Watch These Eli Lilly Stock Price Levels as Weight-Loss Drug Competition Rises

Key TakeawaysEli Lilly shares dropped more than 4% on Thursday as investors assessed the possible impact of a promising new weight-loss injection developed by Viking Therapeutics on the drugmaker’s own anti-obesity drug, Mounjaro.The stock's technicals, including bearish divergence and a decisive close beneath a multi-month uptrend line and the 50-day moving average, point to a potential reversal.Eli Lilly shares may encounter support on the chart from prior price action at $790, $725, and $625.A bars patte ...